ReviewPharmaceuticals (Basel, Switzerland)2022
Molecular Mechanisms of Inflammasome in Ischemic Stroke Pathogenesis.
Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Peiminine-Induced Selective Autophagy of AIM2 Inflammasomes Rescues Cerebral Ischemic Injury.Journal of the American Heart Association · 2026Article
- Obstructive Sleep Apnea Syndrome and Ischemic Stroke: Investigating Inflammatory Mechanisms.Nature and science of sleep · 2026Review
- Stool-derived extracellular vesicles increase inflammasome signaling and regulate the gut-brain axis after stroke in Alzheimer's disease transgenic mice.Experimental neurology · 2025Article
- Molecular mechanisms of programmed cell death and potential targeted pharmacotherapy in ischemic stroke (Review).International journal of molecular medicine · 2025Review
- The Inflammasome-miR Axis in Alzheimer's Disease and Chronic Pain: Molecular Mechanisms and Therapeutic Opportunities.Aging and disease · 2025Review
- Postoperative Serum NLRP1 as a Biochemical Predictor of Delirium and Cognitive Decline After Hip Fracture Surgery in Elderly Patients: A Single Center Observational Study.Clinical interventions in aging · 2025Observational
- Mechanistic exploration of ubiquitination-mediated pathways in cerebral ischemic injury.Molecular biology reports · 2024Review
- Vascular Aging in Ischemic Stroke.Journal of the American Heart Association · 2024Review
- A Prospective Cohort Study of Elevated Serum NLRP1 Levels to Prognosticate Neurological Outcome After Acute Intracerebral Hemorrhage at a Single Academic Institution.Neuropsychiatric disease and treatment · 2024Article
- The Role of Histone Deacetylases in NLRP3 Inflammasomesmediated Epilepsy.Current molecular medicine · 2024Review
- Whole Exome Sequencing in Vaccine-Induced Thrombotic Thrombocytopenia (VITT).BioMed research international · 2024Article
- The NLRP3 inflammasome in ischemic stroke.Frontiers in stroke · 2024Review
- Tat-CCT2 Protects the Neurons from Ischemic Damage by Reducing Oxidative Stress and Activating Autophagic Removal of Damaged Protein in the Gerbil Hippocampus.Neurochemical research · 2023Article
- Exosomal miRNAs as Biomarkers of Ischemic Stroke.Brain sciences · 2023Review
- Proteomic profiling identifies novel inflammation-related plasma proteins associated with ischemic stroke outcome.Journal of neuroinflammation · 2023Article
- Neuroinflammatory Biomarkers in the Brain, Cerebrospinal Fluid, and Blood After Ischemic Stroke.Molecular neurobiology · 2023Review
- Progress in stratified stroke characterization-associated with better diagnosis, accurate prognosis and improved treatment strategies.Brain pathology (Zurich, Switzerland) · 2023Article
- 12/15-lipoxygenase inhibition attenuates neuroinflammation by suppressing inflammasomes.Frontiers in cellular neuroscience · 2023Article
- Editorial: Neuroinflammation and neuroimmune response in experimental MCAO and ischemic stroke.Frontiers in aging neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke (also called cerebral ischemia) is one of the leading causes of death and severe disability worldwide. NLR inflammasomes play a crucial role in sensing cell damage in response to a harmful stimuli and modulating the inflammatory response, promoting the release of pro-inflammatory cytokines such as IL-18 and IL-1β following ischemic injury. Therefore, a neuroprotective effect is achieved by inhibiting the expression, assembly, and secretion of inflammasomes, thus limiting the extent of brain detriment and neurological sequelae. This review aims to illustrate the molecular characteristics, expression levels, and assembly of NLRP3 (nucleotide-binding oligomerization domain-like receptor [NLR] family pyrin-domain-containing 3) inflammasome, the most studied in the literature, in order to discover promising therapeutic implications. In addition, we provide some information regarding the contribution of NLRP1, NLRP2, and NLRC4 inflammasomes to ischemic stroke pathogenesis, highlighting potential therapeutic strategies that require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.